Allen Stephen J, Martinez Elizabeth G, Gregorio Germana V, Dans Leonila F
School of Medicine, Swansea University, Room 314, The Grove Building, Singleton Park, Swansea, West Glamorgan, UK, SA2 8PP.
Cochrane Database Syst Rev. 2010 Nov 10;2010(11):CD003048. doi: 10.1002/14651858.CD003048.pub3.
Probiotics may offer a safe intervention in acute infectious diarrhoea to reduce the duration and severity of the illness.
To assess the effects of probiotics in proven or presumed acute infectious diarrhoea.
We searched the Cochrane Infectious Diseases Group's trials register (July 2010), the Cochrane Controlled Trials Register (The Cochrane Library Issue 2, 2010), MEDLINE (1966 to July 2010), EMBASE (1988 to July 2010), and reference lists from studies and reviews. We also contacted organizations and individuals working in the field, and pharmaceutical companies manufacturing probiotic agents.
Randomized and quasi-randomized controlled trials comparing a specified probiotic agent with a placebo or no probiotic in people with acute diarrhoea that is proven or presumed to be caused by an infectious agent.
Two reviewers independently assessed the methodological quality of the trial and extracted data. Primary outcomes were the mean duration of diarrhoea, stool frequency on day 2 after intervention and ongoing diarrhoea on day 4. A random-effects model was used.
Sixty-three studies met the inclusion criteria with a total of 8014 participants. Of these, 56 trials recruited infants and young children. The trials varied in the definition used for acute diarrhoea and the end of the diarrhoeal illness, as well as in the risk of bias. The trials were undertaken in a wide range of different settings and also varied greatly in organisms tested, dosage, and participants' characteristics. No adverse events were attributed to the probiotic intervention.Probiotics reduced the duration of diarrhoea, although the size of the effect varied considerably between studies.The average of the effect was significant for mean duration of diarrhoea (mean difference 24.76 hours; 95% confidence interval 15.9 to 33.6 hours; n=4555, trials=35) diarrhoea lasting ≥4 days (risk ratio 0.41; 0.32 to 0.53; n=2853, trials=29) and stool frequency on day 2 (mean difference 0.80; 0.45 to 1.14; n=2751, trials=20).The differences in effect size between studies was not explained by study quality, probiotic strain, the number of different strains, the viability of the organisms, dosage of organisms, the causes of diarrhoea, or the severity of the diarrhoea, or whether the studies were done in developed or developing countries.
AUTHORS' CONCLUSIONS: Used alongside rehydration therapy, probiotics appear to be safe and have clear beneficial effects in shortening the duration and reducing stool frequency in acute infectious diarrhoea. However, more research is needed to guide the use of particular probiotic regimens in specific patient groups.
益生菌可能为急性感染性腹泻提供一种安全的干预措施,以缩短病程并减轻病情严重程度。
评估益生菌对确诊或疑似急性感染性腹泻的疗效。
我们检索了Cochrane传染病组试验注册库(2010年7月)、Cochrane对照试验注册库(《Cochrane图书馆》2010年第2期)、MEDLINE(1966年至2010年7月)、EMBASE(1988年至2010年7月),以及研究和综述的参考文献列表。我们还联系了该领域的组织和个人,以及生产益生菌制剂的制药公司。
将特定益生菌制剂与安慰剂或无益生菌在确诊或疑似由感染性病原体引起的急性腹泻患者中进行比较的随机和半随机对照试验。
两名评价员独立评估试验的方法学质量并提取数据。主要结局为腹泻的平均持续时间、干预后第2天的排便频率以及第4天仍存在的腹泻情况。采用随机效应模型。
63项研究符合纳入标准,共有8014名参与者。其中,56项试验招募了婴幼儿。这些试验在急性腹泻和腹泻疾病结束的定义、偏倚风险方面存在差异。试验在广泛的不同环境中进行,在测试的微生物、剂量和参与者特征方面也有很大差异。未发现不良事件归因于益生菌干预。益生菌可缩短腹泻持续时间,尽管不同研究之间效果大小差异很大。腹泻平均持续时间的平均效应显著(平均差24.76小时;95%置信区间15.9至33.6小时;n = 4555,试验 = 35),腹泻持续≥4天(风险比0.41;0.32至0.53;n = 2853,试验 = 29)以及第2天的排便频率(平均差0.80;0.45至1.14;n = 2751,试验 = 20)。研究之间效应大小的差异无法通过研究质量、益生菌菌株、不同菌株数量、微生物活力、微生物剂量、腹泻原因、腹泻严重程度,或研究是在发达国家还是发展中国家进行来解释。
与补液疗法同时使用时,益生菌似乎是安全的,并在缩短急性感染性腹泻病程和减少排便频率方面具有明显的有益效果。然而,需要更多研究来指导特定患者群体中特定益生菌方案的使用。